Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapies for rare diseases. At the forefront of our innovation is Deramiocel (CAP-1002), our lead cell therapy in late-stage development for Duchenne muscular dystrophy. We are also harnessing our proprietary StealthX™ exosome platform to unlock new possibilities in targeted delivery and vaccinology. Every program reflects our commitment to pushing the boundaries of science and delivering life-changing treatments to patients and families who need them most.
This role will serve as the executive leader responsible for building and running the commercial infrastructure that powers Capricor's first launch, Deramiocel, our lead cell therapy for Duchenne muscular dystrophy. This role will design the end-to-end operational backbone that enables a high-performing field organization, disciplined commercial decision-making, and scalable systems across a complex rare disease and advanced-therapy landscape. The ideal candidate brings deep commercial operations expertise, proven leadership launching rare disease or specialty therapies, and a hands-on builder mindset suited for a fast-growing biotech at a pivotal stage of commercialization.